{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:22:57Z","timestamp":1788481377500,"version":"build-2803163510"},"reference-count":96,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This review summarizes the rationale and current data on the use of thrombopoietin receptor agonists (TPO-RAs) for treating severe thrombocytopenia in infants, children, and adolescents. It focuses on substances that have been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for pediatric patients. Romiplostim and eltrombopag are already established as second-line treatment for persistent or chronic immune thrombocytopenia (ITP). As in adults, TPO-RAs are currently also evaluated in severe aplastic anemia (SAA), chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), and poor engraftment after hematopoietic stem cell transplantation in pediatric and adolescent patients. Moreover, studies on the implication of TPO-RA in treating rare inherited thrombocytopenias, such as Wiskott-Aldrich syndrome (WAS), congenital amegakaryocytic thrombocytopenia (CAMT), or MYH9-associated thrombocytopenia, deserve future attention. Current developments include testing of avatrombopag and lusutrombopag that are approved for the treatment of thrombocytopenia associated with chronic liver disease (CLD) in adult patients. In pediatric and adolescent medicine, we expect in the near future a broader use of TPO-RAs as first-line treatment in primary ITP, thereby considering immunomodulatory effects that increase the rate of sustained remission off-treatment, and a selective use in rare inherited thrombocytopenias based on current clinical trials.<\/jats:p>","DOI":"10.1055\/a-2247-4209","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:14:58Z","timestamp":1719429298000},"page":"316-325","source":"Crossref","is-referenced-by-count":12,"title":["Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics"],"prefix":"10.1055","volume":"44","author":[{"given":"Jennifer","family":"Gebetsberger","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Streif","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Dame","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.emc.2021.04.007","article-title":"Pediatric hematologic and oncologic emergencies","volume":"39","author":"K Stephanos","year":"2021","journal-title":"Emerg Med Clin North Am"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.10.001","article-title":"Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates? A systematic review","volume":"36","author":"S F Fustolo-Gunnink","year":"2019","journal-title":"Blood Rev"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/hae.14247","article-title":"Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders","volume":"27","author":"C C Aquino","year":"2021","journal-title":"Haemophilia"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/09537104.2016.1148806","article-title":"Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan","volume":"27","author":"B Johnson","year":"2016","journal-title":"Platelets"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tmrv.2014.11.006","article-title":"Platelets are not just for clots","volume":"29","author":"J D McFadyen","year":"2015","journal-title":"Transfus Med Rev"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474086.2019.1657824","article-title":"Platelet and red cell transfusions for neonates: lifesavers or Trojan horses?","volume":"12","author":"S F Fustolo-Gunnink","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1080\/09537104.2021.1925102","article-title":"The thrombopoietin receptor: revisiting the master regulator of platelet production","volume":"32","author":"I S Hitchcock","year":"2021","journal-title":"Platelets"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"C L Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2003.05.001","article-title":"AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl","volume":"25","author":"V C Broudy","year":"2004","journal-title":"Cytokine"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"J Li","year":"2001","journal-title":"Blood"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"J Gilreath","year":"2021","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"100909","DOI":"10.1016\/j.blre.2021.100909","article-title":"The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag","volume":"53","author":"D J Kuter","year":"2022","journal-title":"Blood Rev"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"100811","DOI":"10.1016\/j.blre.2021.100811","article-title":"Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia","volume":"49","author":"D J Kuter","year":"2021","journal-title":"Blood Rev"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1080\/14712598.2021.1960979","article-title":"Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP)","volume":"21","author":"F Chen","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"680411","DOI":"10.3389\/fonc.2021.680411","article-title":"Off-label use of thrombopoietin receptor agonists: case series and review of the literature","volume":"11","author":"M Capecchi","year":"2021","journal-title":"Front Oncol"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.24011","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study","volume":"90","author":"R K Brynes","year":"2015","journal-title":"Am J Hematol"},{"issue":"18","key":"ref17","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114","author":"D J Kuter","year":"2009","journal-title":"Blood"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"W Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1073\/pnas.0406008102","article-title":"A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain","volume":"102","author":"H Ehrenreich","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1128\/IAI.00782-10","article-title":"Thrombopoietin contributes to neuronal damage in experimental bacterial meningitis","volume":"79","author":"O Hoffmann","year":"2011","journal-title":"Infect Immun"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/jth.13602","article-title":"Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development","volume":"15","author":"T W Bastian","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"C Xie","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"H Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"03","key":"ref24","first-page":"20","article-title":"A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy","volume":"13","author":"G Peng","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"M D Tarantino","year":"2016","journal-title":"Lancet"},{"issue":"50","key":"ref26","doi-asserted-by":"crossref","first-page":"e32345","DOI":"10.1097\/MD.0000000000032345","article-title":"Efficacy and quality of life of romiplostim in adults and children with immune thrombocytopenia: a review","volume":"101","author":"X He","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.htct.2022.09.1275","article-title":"Safety and efficacy of romiplostim in children and adolescents with immune thrombocytopenia: a systematic review","volume":"45","author":"F L de Oliveira","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"issue":"09","key":"ref28","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00277-021-04590-0","article-title":"Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia","volume":"100","author":"J D Grainger","year":"2021","journal-title":"Ann Hematol"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/bloodadvances.2021006014","article-title":"A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia","volume":"7","author":"J Grainger","year":"2023","journal-title":"Blood Adv"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1160\/TH11-07-0474","article-title":"A patient with Fechtner syndrome successfully treated with romiplostim","volume":"107","author":"S Gr\u00f6pper","year":"2012","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00277-015-2416-x","article-title":"A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia","volume":"94","author":"J Yamanouchi","year":"2015","journal-title":"Ann Hematol"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15252\/emmm.201708168","article-title":"Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim","volume":"10","author":"A Pecci","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.17174","article-title":"Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome","volume":"192","author":"A Khoreva","year":"2021","journal-title":"Br J Haematol"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"e29548","DOI":"10.1002\/pbc.29548","article-title":"Chemotherapy-induced thrombocytopenia in Ewing sarcoma: implications and potential for romiplostim supportive care","volume":"69","author":"N Merjaneh","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/jcb.25380","article-title":"C-Mpl is expressed on osteoblasts and osteoclasts and is important in regulating skeletal homeostasis","volume":"117","author":"T E Meijome","year":"2016","journal-title":"J Cell Biochem"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/jcp.24943","article-title":"A novel role for thrombopoietin in regulating osteoclast development in humans and mice","volume":"230","author":"M Bethel","year":"2015","journal-title":"J Cell Physiol"},{"issue":"18","key":"ref37","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"B Will","year":"2009","journal-title":"Blood"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.scr.2012.05.001","article-title":"Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem\/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis","volume":"9","author":"H Sun","year":"2012","journal-title":"Stem Cell Res (Amst)"},{"issue":"17","key":"ref39","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","article-title":"Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator","volume":"130","author":"E Vlachodimitropoulou","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","article-title":"Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation","volume":"120","author":"M Roth","year":"2012","journal-title":"Blood"},{"issue":"458","key":"ref41","doi-asserted-by":"crossref","first-page":"eaas9563","DOI":"10.1126\/scitranslmed.aas9563","article-title":"Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag","volume":"10","author":"Y R Kao","year":"2018","journal-title":"Sci Transl Med"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.18012","article-title":"Eltrombopag in paediatric immune thrombocytopenia: iron metabolism modulation in mesenchymal stromal cells","volume":"197","author":"A Di Paola","year":"2022","journal-title":"Br J Haematol"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","volume":"2","author":"J B Bussel","year":"2015","journal-title":"Lancet Haematol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"J D Grainger","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.3390\/jcm12123872","article-title":"Eltrombopag for adults and children with immune-refractory thrombocytopenic purpura: a systematic review","volume":"12","author":"D FH de Barros Torelli","year":"2023","journal-title":"J Clin Med"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fmed.2020.00066","article-title":"Use of eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)","volume":"7","author":"P Giordano","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"2210906","DOI":"10.1080\/16078454.2023.2210906","article-title":"Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy","volume":"28","author":"G Palumbo","year":"2023","journal-title":"Hematology"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjh.18842","article-title":"Sustained response off treatment in eltrombopag for children with persistent\/chronic primary immune thrombocytopenia: a multicentre observational retrospective study in China","volume":"202","author":"Z Wang","year":"2023","journal-title":"Br J Haematol"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00277-022-04804-z","article-title":"Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from Lebanon","volume":"101","author":"P Noun","year":"2022","journal-title":"Ann Hematol"},{"issue":"19","key":"ref50","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1182\/bloodadvances.2020004110","article-title":"Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice","volume":"5","author":"X Cheng","year":"2021","journal-title":"Blood Adv"},{"issue":"03","key":"ref51","first-page":"139","article-title":"Outcomes of eltrombopag treatment and development of iron deficiency in children with immune thrombocytopenia in Turkey","volume":"37","author":"A Koca Yozgat","year":"2020","journal-title":"Turk J Haematol"},{"issue":"05","key":"ref52","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00277-022-04784-0","article-title":"Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis","volume":"101","author":"H Zhou","year":"2022","journal-title":"Ann Hematol"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"e29447","DOI":"10.1002\/pbc.29447","article-title":"Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: a systematic review and meta-analysis of prospective clinical trials","volume":"69","author":"N Ayad","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"08","key":"ref54","doi-asserted-by":"crossref","first-page":"e044885","DOI":"10.1136\/bmjopen-2020-044885","article-title":"Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol","volume":"11","author":"K A Shimano","year":"2021","journal-title":"BMJ Open"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"101286","DOI":"10.1016\/j.beha.2021.101286","article-title":"Congenital amegakaryocytic thrombocytopenia - not a single disease","volume":"34","author":"M Germeshausen","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"05","key":"ref56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.exphem.2010.02.007","article-title":"F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents","volume":"38","author":"N E Fox","year":"2010","journal-title":"Exp Hematol"},{"issue":"26","key":"ref57","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1182\/blood-2010-08-304725","article-title":"Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations","volume":"116","author":"A Pecci","year":"2010","journal-title":"Blood"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3324\/haematol.2019.223966","article-title":"Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial","volume":"105","author":"C Zaninetti","year":"2020","journal-title":"Haematologica"},{"issue":"08","key":"ref59","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1002\/ajh.25500","article-title":"Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia","volume":"94","author":"C Zaninetti","year":"2019","journal-title":"Am J Hematol"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1160\/TH12-01-0005","article-title":"Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation","volume":"107","author":"A Pecci","year":"2012","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1542\/peds.2012-3807","article-title":"First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia","volume":"132","author":"R Favier","year":"2013","journal-title":"Pediatrics"},{"issue":"09","key":"ref62","first-page":"1074","article-title":"[Hereditary thrombocytopenia associated with a mutation in the MYH-9 gene. Report of one case]","volume":"146","author":"G Conte","year":"2018","journal-title":"Rev Med Chil"},{"issue":"12","key":"ref63","first-page":"1839","article-title":"Successful eltrombopag therapy in a child with MYH9-related inherited thrombocytopenia","volume":"9","author":"G Lassandro","year":"2022","journal-title":"Children (Basel)"},{"issue":"12","key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26692","article-title":"Eltrombopag use in a patient with Wiskott-Aldrich syndrome","volume":"64","author":"M Gabelli","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"ref65","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"126","author":"A J Gerrits","year":"2015","journal-title":"Blood"},{"issue":"08","key":"ref66","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1080\/09537104.2016.1190446","article-title":"Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia","volume":"27","author":"M Fiore","year":"2016","journal-title":"Platelets"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.V96.1.118","article-title":"Autosomal dominant thrombocytopenia: incomplete megakaryocyte differentiation and linkage to human chromosome 10","volume":"96","author":"J G Drachman","year":"2000","journal-title":"Blood"},{"issue":"25","key":"ref68","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"J B Bussel","year":"2014","journal-title":"Blood"},{"issue":"16","key":"ref69","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","article-title":"Avatrombopag: a review in thrombocytopenia","volume":"81","author":"A Markham","year":"2021","journal-title":"Drugs"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/08971900221125827","article-title":"Avatrombopag for the treatment of immune thrombocytopenia and periprocedural thrombocytopenia associated with chronic liver disease","volume":"37","author":"T B Tran","year":"2024","journal-title":"J Pharm Pract"},{"issue":"08","key":"ref71","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/1744666X.2022.2098119","article-title":"An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia","volume":"18","author":"A B Song","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"03","key":"ref72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/TCRM.S251672","article-title":"Avatrombopag for the treatment of adult patients with chronic immune thrombocytopenia (cITP): focus on patient selection and perspectives","volume":"18","author":"G Tsykunova","year":"2022","journal-title":"Ther Clin Risk Manag"},{"issue":"07","key":"ref73","doi-asserted-by":"crossref","first-page":"704093","DOI":"10.3389\/fphar.2021.704093","article-title":"Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial","volume":"12","author":"J Deng","year":"2021","journal-title":"Front Pharmacol"},{"issue":"03","key":"ref74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"H Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"issue":"08","key":"ref75","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/09537104.2022.2096211","article-title":"Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure","volume":"33","author":"A R Arif","year":"2022","journal-title":"Platelets"},{"issue":"16","key":"ref76","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"C Neunert","year":"2011","journal-title":"Blood"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12185-022-03527-1","article-title":"Recent progress in ITP treatment","volume":"117","author":"F Rodeghiero","year":"2023","journal-title":"Int J Hematol"},{"issue":"05","key":"ref78","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bcpt.12815","article-title":"Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals","volume":"121","author":"L Zheng","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"ref79","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1111\/jth.15078","article-title":"First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura","volume":"18","author":"Z Wang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/etm.2023.12092","article-title":"Safety of non\u2013peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: a systematic review and meta\u2013analysis of short\u2013term double\u2013blind randomized clinical trials","volume":"26","author":"N Shen","year":"2023","journal-title":"Exp Ther Med"},{"issue":"07","key":"ref81","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1080\/09537104.2019.1572873","article-title":"Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis","volume":"30","author":"J Tumaini Massaro","year":"2019","journal-title":"Platelets"},{"issue":"08","key":"ref82","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/pbc.26003","article-title":"Thrombopoietin receptor agonist use in children: data from the pediatric ITP Consortium of North America ICON2 Study","volume":"63","author":"C Neunert","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"05","key":"ref83","first-page":"20","article-title":"Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia","volume":"10","author":"J R Gonz\u00e1lez-Porras","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"03","key":"ref84","first-page":"307","article-title":"Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review","volume":"16","author":"F Depr\u00e9","year":"2018","journal-title":"Blood Transfus"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"2267942","DOI":"10.1080\/16078454.2023.2267942","article-title":"Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the Netherlands (TRAPeze Netherlands study)","volume":"28","author":"A JG Jansen","year":"2023","journal-title":"Hematology"},{"issue":"03","key":"ref86","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bjh.18864","article-title":"Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: a real-world study in China","volume":"202","author":"X Cheng","year":"2023","journal-title":"Br J Haematol"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"16680","DOI":"10.1038\/s41598-019-53209-y","article-title":"Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia","volume":"9","author":"M L Lozano","year":"2019","journal-title":"Sci Rep"},{"issue":"22","key":"ref88","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"W Bao","year":"2010","journal-title":"Blood"},{"issue":"12","key":"ref89","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1600-065X.2007.00565.x","article-title":"\u2018Yin-Yang\u2019 functions of transforming growth factor-beta and T regulatory cells in immune regulation","volume":"220","author":"Y Y Wan","year":"2007","journal-title":"Immunol Rev"},{"issue":"S 01","key":"ref90","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/j.seminhematol.2016.04.010","article-title":"Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?","volume":"53","author":"A Schifferli","year":"2016","journal-title":"Semin Hematol"},{"issue":"02","key":"ref91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"A Zufferey","year":"2017","journal-title":"J Clin Med"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/ijms22010097","article-title":"Effects of eltrombopag on in vitro macrophage polarization in pediatric immune thrombocytopenia","volume":"22","author":"A Di Paola","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref93","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bjh.19074","article-title":"Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: the iROM study","volume":"203","author":"A Schifferli","year":"2023","journal-title":"Br J Haematol"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"A Newland","year":"2016","journal-title":"Br J Haematol"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"2135694","DOI":"10.1080\/09537104.2022.2135694","article-title":"Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes\/macrophages in immune thrombocytopenia","volume":"34","author":"F Yang","year":"2023","journal-title":"Platelets"},{"issue":"01","key":"ref96","doi-asserted-by":"crossref","first-page":"9401","DOI":"10.1038\/s41598-021-88900-6","article-title":"Platelet function and bleeding at different phases of childhood immune thrombocytopenia","volume":"11","author":"A A Ignatova","year":"2021","journal-title":"Sci Rep"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2247-4209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:46:47Z","timestamp":1730807207000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2247-4209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":96,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,8,16]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2247-4209","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}